Cardiovascular disease mortality in kidney transplant recipients: No light at the end of the tunnel?

American Journal of Kidney Diseases

Volumn 59, Issue 6, 2012, Pages 754-757

  Sunder Plassmann, Gere ^a   Födinger, Manuela ^b   Säemann, Marcus D ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DRUG MECHANISM; DRUG MEGADOSE; GRAFT RECIPIENT; HEALTH CARE PERSONNEL; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY TRANSPLANT RECIPIENT; LOW DRUG DOSE; MORTALITY; NOTE; PROTEIN BLOOD LEVEL; SURVIVAL RATE;

EID: 84861347188     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.11.022     Document Type: Editorial

References (24)

1. L. Liefeldt, K. Budde Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk Transpl Int 23 12 2010 1191 1204
2. H.U. Meier-Kriesche, R. Baliga, B. Kaplan Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation Transplantation 75 8 2003 1291 1295
3. H.U. Meier-Kriesche, J.D. Schold, T.R. Srinivas, A. Reed, B. Kaplan Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease Am J Transplant 4 10 2004 1662 1668
4. G. Opelz, B. Döhler Improved long-term outcomes after renal transplantation associated with blood pressure control Am J Transplant 5 11 2005 2725 2731
5. H. Holdaas, B. Fellström, A.G. Jardine Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial Lancet 361 9374 2003 2024 2031
6. H. Holdaas, B. Fellström, E. Cole Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study Am J Transplant 5 12 2005 2929 2936
7. T.G. Valderhaug, J. Hjelmesaeth, A. Hartmann The association of early post-transplant glucose levels with long-term mortality Diabetologia 54 6 2011 1341 1349
8. W.C. Winkelmayer, R. Kramar, G.C. Curhan Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study J Am Soc Nephrol 16 1 2005 255 260
9. R. Clarke, J. Halsey, S. Lewington Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals Arch Intern Med 170 18 2010 1622 1631
10. G. Sunder-Plassmann, W.C. Winkelmayer, M. Födinger Approaching the end of the homocysteine hype? Am J Kidney Dis 51 4 2008 549 553
11. A.G. Bostom, M.A. Carpenter, J.W. Kusek Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial Am Heart J 152 3 2006 448 e441-447
12. A.G. Bostom, M.A. Carpenter, J.W. Kusek Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial Circulation 123 16 2011 1763 1770
13. E.M. Wrone, J.M. Hornberger, J.L. Zehnder, L.M. McCann, N.S. Coplon, S.P. Fortmann Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease J Am Soc Nephrol 15 2 2004 420 426
14. J.F. Mann, P. Sheridan, M.J. McQueen Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease - results of the renal HOPE-2 Study Nephrol Dial Transplant 23 2 2008 645 653
15. R.L. Jamison, P. Hartigan, J.S. Kaufman Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial JAMA 298 10 2007 1163 1170
16. J. Heinz, S. Kropf, U. Domröse B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial Circulation 121 12 2010 1432 1438
17. S. Zoungas, B.P. McGrath, P. Branley Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial J Am Coll Cardiol 47 6 2006 1108 1116
18. A.C. Vianna, A.J. Mocelin, T. Matsuo Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events Hemodial Int 11 2 2007 210 216
19. A.A. House, M. Eliasziw, D.C. Cattran Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial JAMA 303 16 2010 1603 1609
20. M. Righetti, G.M. Ferrario, S. Milani Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients Med Sci Monit 9 4 2003 PI19 PI24
21. M. Righetti, P. Serbelloni, S. Milani, G. Ferrario Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients Blood Purif 24 4 2006 379 386
22. J. Heinz, S. Kropf, C. Luley, J. Dierkes Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis Am J Kidney Dis 54 3 2009 478 489
23. X. Qin, Y. Huo, C.B. Langman Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis Clin J Am Soc Nephrol 6 3 2011 482 488
24. A. Webber, R. Hirose, F. Vincenti Novel strategies in immunosuppression: issues in perspective Transplantation 91 10 2011 1057 1064